MAUNA KEA TECHNOLOGIES AI Stock Analysis
Want to see FR:ALMKT full AI Analyst Report?
MAUNA KEA TECHNOLOGIES (ALMKT) AI Stock Analysis
MAUNA KEA TECHNOLOGIES
(Paris:ALMKT)
The score is held down primarily by weak financial quality—persistent operating losses, ongoing cash burn, and negative equity—despite improved revenue and strong gross margins. Technicals also remain bearish with the stock below key moving averages, only partially tempered by very oversold RSI. A low P/E provides some valuation support, but sustainability concerns keep the overall score low.
MAUNA KEA TECHNOLOGIES (ALMKT) vs. iShares MSCI France ETF (EWQ)
- Market Cap
- EUR 18.02M
- Dividend Yield
- ―
- Average Volume (3M)
- 508.84K
- Price to Earnings (P/E)
- 1.5
- Beta (1Y)
- 0.99
- Revenue Growth
- 3.38%
- EPS Growth
- ―
- Country
- France
- Employees
- 56
- Sector
- General
- Sector Strength
- 55
- Industry
- Medical - Devices
MAUNA KEA TECHNOLOGIES Business Overview & Revenue Model
Company Description
Mauna Kea Technologies SA operates as a medical device enterprise, producing and distributing its offerings throughout Europe and worldwide. Its product line serves various medical specialties such as gastroenterology, pulmonology, and urology. Centr...
How the Company Makes Money
The company primarily makes money by selling its Cellvizio endomicroscopy platform and related consumables. Key revenue streams typically include: (1) sales of capital equipment (the Cellvizio imaging system) to hospitals and endoscopy centers; (2) r...
MAUNA KEA TECHNOLOGIES Financial Statement Overview
Summary
Despite a 2025 revenue rebound and strong ~75% gross margin, fundamentals remain stressed: operating margin is deeply negative (~-83%), operating/free cash flow are still negative, and shareholders’ equity remains negative (solvency risk). The swing to large net profit in 2025 appears not supported by operating performance or cash generation, reducing durability.
Income Statement
33NegativeBalance Sheet
18Very NegativeCash Flow
22Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.73M | 8.22M | 7.66M | 11.03M | 7.48M | 7.70M |
| Gross Profit | 5.01M | 6.20M | 6.44M | 8.93M | 3.91M | 5.71M |
| EBITDA | -6.34M | 12.87M | -7.97M | -1.46M | -9.93M | -11.23M |
| Net Income | 9.94M | 10.77M | -10.40M | -3.73M | -11.18M | -13.45M |
Balance Sheet | ||||||
| Total Assets | 10.22M | 13.41M | 16.25M | 22.94M | 19.79M | 24.75M |
| Cash, Cash Equivalents and Short-Term Investments | 2.35M | 4.97M | 1.92M | 7.91M | 3.15M | 11.89M |
| Total Debt | 11.83M | 12.08M | 31.93M | 29.77M | 29.20M | 28.70M |
| Total Liabilities | 18.01M | 18.23M | 40.63M | 40.21M | 39.72M | 35.08M |
| Stockholders Equity | -7.79M | -4.82M | -24.39M | -17.28M | -19.92M | -10.33M |
Cash Flow | ||||||
| Free Cash Flow | -4.43M | -3.95M | -6.54M | -1.14M | -8.97M | -11.37M |
| Operating Cash Flow | -4.24M | -3.74M | -6.32M | -753.00K | -8.83M | -10.27M |
| Investing Cash Flow | -443.00K | -200.00K | -149.00K | -354.00K | -57.00K | -1.14M |
| Financing Cash Flow | 6.36M | 6.95M | 483.00K | 5.96M | 109.00K | 14.65M |
MAUNA KEA TECHNOLOGIES Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALMKT, the sentiment is Negative. The current price of 0.09 is below the 20-day moving average (MA) of 0.10, below the 50-day MA of 0.12, and below the 200-day MA of 0.16, indicating a bearish trend. The MACD of -0.01 indicates Negative momentum. The RSI at 31.80 is Neutral, neither overbought nor oversold. The STOCH value of 53.33 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALMKT.
MAUNA KEA TECHNOLOGIES Peers Comparison
Overall Rating
FR:ALERS58Neutral
FR:ALIKO46Neutral
FR:ALTHE46Neutral
FR:ALNOV45Neutral- FR:ALMKT45Neutral
FR:ALMDT43Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| FR:ALERS | 58Neutral | EUR 258.89M | 37.71 | 3.89% | ― | 6.28% | 204.56% |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| FR:ALIKO | 46Neutral | EUR 22.89M | -5.31 | -22.49% | ― | 37.28% | 7.83% |
| FR:ALTHE | 46Neutral | EUR 46.78M | -5.74 | 453.10% | ― | -16.98% | 20.31% |
| FR:ALNOV | 45Neutral | EUR 31.21M | -0.78 | -159.70% | ― | 10.36% | 29.41% |
| FR:ALMKT | 45Neutral | EUR 18.02M | 1.46 | -157.72% | ― | 3.38% | ― |
| FR:ALMDT | 43Neutral | EUR 208.54M | -3.54 | 271.64% | ― | 2.16% | -5.26% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| FR:ALMKT | MAUNA KEA TECHNOLOGIES | 0.09 | 0.01 | 9.52% | |
| FR:ALTHE | Theraclion SA | 0.59 | -0.09 | -12.65% | |
| FR:ALNOV | Novacyt S.A. | 0.45 | 0.01 | 1.58% | |
| FR:ALERS | Eurobio-Scientific SA | 26.40 | 1.55 | 6.24% | |
| FR:ALIKO | Ikonisys SA | 1.45 | -0.01 | -0.68% | |
| FR:ALMDT | Median Technologies | 4.36 | 1.40 | 47.30% |
MAUNA KEA TECHNOLOGIES Corporate Events
Mauna Kea Highlights Cellvizio for Pancreatic Cyst Assessment
Mauna Kea Technologies, a global medical device company, said Cellvizio provides real-time, cellular visualization of the inner wall of pancreatic cysts during endoscopic procedures. The company cited pancreatic cyst lesions detected by chance in 3%...
Mauna Kea Technologies Discloses Share and Voting-Right Totals as of 31 October 2026
Mauna Kea Technologies reported 199,078,750 shares outstanding and 200,166,551 gross and net voting rights as of 31 October 2026. The regulatory disclosure provides the company’s share-capital and voting-rights totals, with gross rights including all...
Mauna Kea Launches CellTolerance Program in Abu Dhabi
Mauna Kea Technologies develops and markets Cellvizio, a probe- and needle-based imaging platform for real-time cellular visualization during medical examinations. Its applications include gastrointestinal disease assessment, pancreatic cyst evaluati...
Mauna Kea’s Revenue Climbs on International Growth as U.S. Salesforce Rebuilds
Mauna Kea Technologies reported nine-month 2026 revenue of €4.4 million, up 24% at constant exchange rates, driven by a 17% rise in recurring probe and service revenue and a 128% surge in Europe and Rest of World sales, where six systems were sold an...
Mauna Kea lifts core revenue on CellTolerance momentum and extends cash runway to 2027
Mauna Kea Technologies reported a 37% rise in product and service revenue to €3.2 million in the first half of 2026, driven by strong uptake of its CellTolerance solution in Europe and initial sales in markets including the UAE, Switzerland, Australi...
Mauna Kea Discloses Updated Share Capital and Voting Rights Structure
Mauna Kea Technologies reported that as of 30 September 2026, its share capital comprised 199,066,710 shares listed on Euronext Growth Paris, corresponding to 200,153,761 gross and net voting rights. The disclosure, made under French market regulatio...
Mauna Kea Technologies Updates Share Capital and Voting Rights After New Share Issuance
Mauna Kea Technologies reported updated share capital and voting rights as of August 31, 2026, with 198,626,997 shares outstanding and 199,714,048 gross and net voting rights. The figures reflect the issuance of 3,100,000 new shares during the month...
Independent Meta-Analysis Strengthens Case for Mauna Kea’s Cellvizio in GI Cancer
A landmark independent systematic review and meta-analysis from Korea’s National Evidence-Based Healthcare Collaborating Agency has validated probe-based confocal laser endomicroscopy in upper gastrointestinal cancer. Pooling 33 studies and 2,350 pat...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 03, 2026